An overview of the mTOR pathway as a target in cancer therapy
暂无分享,去创建一个
[1] J. Diamond,et al. [Mechanisms of resistance to BCR-ABL kinase inhibitors]. , 2013, Acta medica portuguesa.
[2] J. Tamburini,et al. The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia , 2012, Leukemia.
[3] M. Piccart,et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.
[4] K. Flatten,et al. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. , 2012, Blood.
[5] J. Castillo,et al. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies , 2012, Expert opinion on investigational drugs.
[6] J. Stockman,et al. Everolimus for Advanced Pancreatic Neuroendocrine Tumors , 2012 .
[7] J. Blay,et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Daniela Cilloni,et al. Molecular Pathways: BCR-ABL , 2011, Clinical Cancer Research.
[9] E. Dazert,et al. mTOR signaling in disease. , 2011, Current opinion in cell biology.
[10] J. Balko,et al. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] V. Rodrik-Outmezguine,et al. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1 , 2011, Cell cycle.
[12] L. Platanias,et al. Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies , 2011, Current opinion in oncology.
[13] A. Wiestner,et al. New molecular targets in mantle cell lymphoma. , 2011, Seminars in cancer biology.
[14] M. Hall,et al. Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.
[15] D. Ettinger,et al. A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomas , 2011, Cancer.
[16] M. Atkins,et al. Future directions in renal cell carcinoma: 2011 and beyond. , 2011, Hematology/oncology clinics of North America.
[17] R. Motzer,et al. mTOR inhibitors in advanced renal cell carcinoma. , 2011, Hematology/oncology clinics of North America.
[18] L. Platanias,et al. Targeting mTOR for the treatment of AML. New agents and new directions , 2011, Oncotarget.
[19] M. Sanchez-Cespedes,et al. The role of LKB1 in lung cancer , 2011, Familial Cancer.
[20] A. Redig,et al. Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors , 2011, Clinical Cancer Research.
[21] J. Carew,et al. Mechanisms of mTOR inhibitor resistance in cancer therapy , 2011, Targeted Oncology.
[22] Michael A. Choti,et al. DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.
[23] V. Zinzalla,et al. Activation of mTORC2 by Association with the Ribosome , 2011, Cell.
[24] H. Kantarjian,et al. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] A. Redig,et al. Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR–ABL , 2011, Leukemia & lymphoma.
[26] H. Kantarjian,et al. New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia , 2011, Leukemia & lymphoma.
[27] Thomas Ernst,et al. Impact of BCR-ABL mutations on patients with chronic myeloid leukemia , 2011, Cell cycle.
[28] M. Talpaz,et al. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia , 2011, Leukemia.
[29] R. Ulrich,et al. Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma , 2010 .
[30] N. Schmitz,et al. CNS Disease In Younger Patients ( , 2010 .
[31] Jiang Li,et al. mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells , 2010, Molecular Cancer.
[32] S. Signoretti,et al. The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma , 2010, Clinical Cancer Research.
[33] L. Platanias,et al. Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells , 2010, Proceedings of the National Academy of Sciences.
[34] A. Nakashima,et al. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer , 2010, Oncogene.
[35] Jing Chen,et al. Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor , 2010, Nature Medicine.
[36] C. Croce,et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] L. Platanias,et al. Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells. , 2010, Autophagy.
[38] A. Kibel. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2009 .
[39] B. Coiffier,et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] J. McCubrey,et al. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. , 2009, Cancer research.
[41] D. Sabatini,et al. An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1* , 2009, Journal of Biological Chemistry.
[42] D. A. Foster,et al. Regulation of mTORC1 and mTORC2 Complex Assembly by Phosphatidic Acid: Competition with Rapamycin , 2008, Molecular and Cellular Biology.
[43] M. Ohh,et al. Differential Dependence of Hypoxia-inducible Factors 1α and 2α on mTORC1 and mTORC2* , 2008, Journal of Biological Chemistry.
[44] B. Manning,et al. Common corruption of the mTOR signaling network in human tumors , 2008, Oncogene.
[45] F. Callera,et al. Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome. , 2008, Leukemia research.
[46] L. Cantley,et al. PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.
[47] K. Shokat,et al. Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells. , 2008, The Journal of clinical investigation.
[48] R. Motzer,et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.
[49] Daniela Gabriel,et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.
[50] K. Shokat,et al. PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML , 2008, Leukemia.
[51] Wolfgang Link,et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. , 2008, Current cancer drug targets.
[52] L. Platanias,et al. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies , 2008, Current opinion in hematology.
[53] O. Haas,et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib‐resistant chronic myeloid leukaemia , 2007, European journal of clinical investigation.
[54] M. Konopleva,et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML , 2008, Leukemia.
[55] J. Tamburini,et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. , 2008, Blood.
[56] Robert T Abraham,et al. Targeting the mTOR signaling network in cancer. , 2007, Trends in molecular medicine.
[57] E. Campo,et al. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics , 2007, Nature Reviews Cancer.
[58] David McDermott,et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.
[59] N. Hay,et al. The two TORCs and Akt. , 2007, Developmental cell.
[60] James Brugarolas,et al. Renal-cell carcinoma--molecular pathways and therapies. , 2007, The New England journal of medicine.
[61] N. Sonenberg,et al. mTOR, translation initiation and cancer , 2006, Oncogene.
[62] D. Sabatini. mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.
[63] D. Sabatini,et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.
[64] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[65] N. Sonenberg,et al. mTOR signaling: implications for cancer and anticancer therapy , 2005, British Journal of Cancer.
[66] Steven P. Gygi,et al. mTOR and S6K1 Mediate Assembly of the Translation Preinitiation Complex through Dynamic Protein Interchange and Ordered Phosphorylation Events , 2005, Cell.
[67] F. Khuri,et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.
[68] R. Fonseca,et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] G. Laurent,et al. Antileukemic activity of rapamycin in acute myeloid leukemia. , 2005, Blood.
[70] N. Sonenberg,et al. Upstream and downstream of mTOR. , 2004, Genes & development.
[71] T. Golub,et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.
[72] W. Kaelin,et al. Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.
[73] L. Cantley,et al. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.
[74] P. Meltzer,et al. Mechanisms of sarcoma development , 2003, Nature Reviews Cancer.
[75] J. Radich,et al. The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.
[76] M. Carroll,et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. , 2003, Blood.
[77] D. A. Foster,et al. Phospholipase D confers rapamycin resistance in human breast cancer cells , 2003, Oncogene.
[78] Shile Huang,et al. Rapamycins: Mechanisms of Action and Cellular Resistance , 2003, Cancer biology & therapy.
[79] Jie Chen,et al. Phosphatidic Acid-Mediated Mitogenic Activation of mTOR Signaling , 2001, Science.
[80] J. Melo,et al. The molecular biology of chronic myeloid leukemia. , 2000, Blood.
[81] S. Gygi,et al. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. , 1999, Genes & development.
[82] A. Gingras,et al. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. , 1999, Annual review of biochemistry.
[83] M. Birnbaum,et al. Insulin Increases the Association of Akt-2 with Glut4-containing Vesicles* , 1998, The Journal of Biological Chemistry.
[84] S Povey,et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. , 1997, Science.
[85] S. Schreiber,et al. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin-associated protein and characterization of a critical serine residue. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[86] Stuart L. Schreiber,et al. A mammalian protein targeted by G1-arresting rapamycin–receptor complex , 1994, Nature.
[87] J. Douros,et al. New antitumor substances of natural origin. , 1981, Cancer treatment reviews.
[88] S. Sehgal,et al. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.
[89] S. Sehgal,et al. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. , 1975, The Journal of antibiotics.